Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/1999
11/30/1999US5994343 Carbapenem antibacterial compounds, compositions containing such compounds and methods of treatment
11/30/1999US5994342 3-(substituted methyl)-4-oxa-1-azabicyclo[3.2.0]heptan-7-one derivatives useful as antitumor agents
11/30/1999US5994341 Anti-angiogenic Compositions and methods for the treatment of arthritis
11/30/1999US5994340 Synergistic mixture with antibiotics
11/30/1999US5994338 Stabilized pharmaceutical compositions, with quinupristine and dalfopristine base and their preparation
11/30/1999US5994337 Adjustment insulin sensitivity
11/30/1999US5994335 17-azolyl steroids useful as androgen synthesis inhibitors
11/30/1999US5994334 Androgen synthesis inhibitors
11/30/1999US5994333 Pregnane and cholane steroids as neurochemical initiators of change in human hypothalamic function and related pharmaceutical compositions and methods
11/30/1999US5994332 Antiinflammatory agents; immunomodulators; skin disorders
11/30/1999US5994330 Topical application of muscarinic agents such as neostigmine for treatment of acne and other inflammatory conditions
11/30/1999US5994329 Adminitering a bisphosphonate; alendronate sodium
11/30/1999US5994328 Hypoestoxides, derivatives and agonists thereof for use as anticancer agents
11/30/1999US5994326 Using raffinose
11/30/1999US5994325 Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
11/30/1999US5994324 Water-soluble vitamin composition having excellent tablet properties and process for production thereof
11/30/1999US5994323 Pharmaceutical compositions comprising clioquinol in combination with vitamin B12 and therapeutic and prophylactic uses thereof
11/30/1999US5994322 Compositions for preventing dementia
11/30/1999US5994317 Quaternary cytofectins
11/30/1999US5994315 Low adenosine agent, composition, kit and method for treatment of airway disease
11/30/1999US5994314 Compositions and methods for nucleic acid delivery to the lung
11/30/1999US5994312 Peptidyl compounds
11/30/1999US5994294 Nitrosated and nitrosylated α-adrenergic receptor antagonist compounds, compositions and their uses
11/30/1999US5994151 Selenium-carrier conjugate comprises (i) an organic selenium compound with atleast one reactive group selected from amino, aldehyde, alcohol, phosphate, sulfate, halogen and phenol(ii) a carrier which is covelently attached with reactive group
11/30/1999US5994127 In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
11/30/1999US5994119 Mammalian regulator of nonsense-mediated RNA decay
11/30/1999US5994101 DNA encoding gidA1 polypeptides
11/30/1999US5994100 HAS2 splicing variant HOEFC11: a target in chronic renal failure, inflammatory diseases and myocardial ischemia
11/30/1999US5994098 G protein coupled receptor gene; treatment of pain, diabetes, eating disorders, asthma; hypotensive/hypertensive agents; parkinson's/huntington's/cardiovascular diseases, ulcers, anticarcinogenic/antiallergens agents; osteoprosis,
11/30/1999US5994096 Regulator
11/30/1999US5994086 Method for assessing infertility by binding of mannose to sperm cells
11/30/1999US5993867 Capsules containing freeze-dried, powdered green tea leaves
11/30/1999US5993863 Contains sugars, amino acids, electrolytes and a fat emulsion at a specific mixing ratio and has a specific ph value and a titratable acidity.
11/30/1999US5993860 Powdered hydrocolloid gum obtainable from higher plants; dispersion-enhancing; and nsaid. exhibits a mucosal protective effect
11/30/1999US5993859 Pharmaceutical agents
11/30/1999US5993856 Pharmaceutical preparations and methods for their administration
11/30/1999US5993845 Histone deacetylase inhibitor and a pharmaceutically acceptable carrier wherein the composition comprises from 0.05 to 100 mg of the histone deacetylase inhibitor.
11/30/1999US5993841 Treating or disorder of the nervous system comprising topically applying an antibiotic; an antihistamine; and a carrier; wherein said antibiotic and said antihistamine are present in relative amounts of 30:70 to 70:30% by weight
11/30/1999US5993836 Topical anesthetic formulation
11/30/1999US5993833 Histamine antagonist, an interleukin-1 antagonist and/or a TNF alpha antagonist in a cosmetic, pharmaceutical or dermatological composition
11/30/1999US5993830 Combining a fatty acid, triethanolamine, propylene glycol, polyvinylpyrrolidone, polydimethylsiloxane, and either glycerol, sorbitol or polyethylene glycol
11/30/1999US5993797 Administering a sulfated polysaccharide from a sea cucumber, which sulfated polysaccharide is an fgag polysaccharide or is obtained by depolymerization of the fgag polysaccharide.
11/30/1999US5993790 Containing a preservative, urea, and a natural additive
11/30/1999US5993788 Polysaccharide alkyl ether. protecting skin and hair against damaging effects of ultraviolet radiation.
11/30/1999US5993787 Composition base for topical therapeutic and cosmetic preparations
11/30/1999US5993783 Aerosols
11/30/1999US5993781 Fluticasone propionate nebulizable formulations
11/30/1999US5993779 Interrupting an aorta at least at two sites, forming an isolated segment including branched parts of radicular arteries, feeding the spinal cord between the sites of interruption, bringing to ischemia, administering glu or asp
11/30/1999US5993777 Benzamide compounds for cancer imaging and therapy
11/30/1999US5993774 Metal-oxime chelates for use as radiopharmaceutical agents
11/30/1999CA2239331C Pharmaceutical tablets comprising cefuroxime axetil
11/30/1999CA2180648C Aqueous topical anti-acne compositions of low ph
11/30/1999CA2179011C 7-(2-imidazolinylamino)quinoline compounds useful as alpha-2 adrenoceptor agonists
11/30/1999CA2166774C Pharmaceutical composition for immunomodulating and adjuvant treatment
11/30/1999CA2098495C 1,4-benzothiazepine derivatives
11/30/1999CA2075282C Alternative enzyme substrates as deodorants
11/30/1999CA2007764C Salsalate tablet
11/30/1999CA1340836C Mixed compositions for treating hypercholesterolemia
11/30/1999CA1340831C Ribozymes
11/26/1999CA2272840A1 Association of a retinoid with a histidine derivative
11/25/1999WO1999060171A1 Compounds, screening methods, and uses involving anti-apoptotic genes and gene products
11/25/1999WO1999060167A1 Compositions and methods for topical delivery of oligonucleotides
11/25/1999WO1999060166A1 Compositions and methods for the pulmonary delivery of nucleic acids
11/25/1999WO1999060146A1 Adeno-associated virus vectors and uses thereof
11/25/1999WO1999060131A2 Hemorrhagic enteritis virus dna sequences, proteins encoded thereby and various uses thereof
11/25/1999WO1999060097A1 clpX OF $i(STREPTOCOCCUS PNEUMONIAE)
11/25/1999WO1999060021A2 Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
11/25/1999WO1999060017A2 Human tumour-derived polypeptide hormone phosphatonin
11/25/1999WO1999060015A1 Imidazolidine derivatives, the production thereof, their use and pharmaceutical preparations containing the same
11/25/1999WO1999060012A1 Compositions and methods for non-parenteral delivery of oligonucleotides
11/25/1999WO1999060008A1 Cytosine deaminase gene
11/25/1999WO1999059997A1 Novel 1,3,8-triazaspiro[4.5]decanones with high affinity for opioid receptor subtypes
11/25/1999WO1999059996A1 Antitumour 1,5-diazaanthraquinones
11/25/1999WO1999059994A1 Retroviral protease inhibiting compounds
11/25/1999WO1999059992A1 Thienyl substituted acylguanidines as inhibitors of bone resorption and vitronectin receptor antagonists
11/25/1999WO1999059989A1 Process for the preparation of a benzo fused heterocyclo sulfonyl halide intermediate
11/25/1999WO1999059987A1 5-demethoxyfumagillol derivatives and processes for preparing the same
11/25/1999WO1999059986A1 Fumagillol derivatives and processes for preparing the same
11/25/1999WO1999059984A1 3-substituted 5-aryl-4-isoxazolecarbonitriles having antiviral activity
11/25/1999WO1999059981A1 Thermally stable trimetrexates and processes for producing the same
11/25/1999WO1999059980A1 [2-alkyl-5-halogeno-6-(4-trifluoromethylphenyl)-4-pyrimidinylamino]acetamide derivatives, process for producing the same, medicinal composition containing the same, and intermediates for the compounds
11/25/1999WO1999059975A1 Fused tricyclic compounds which inhibit parp activity
11/25/1999WO1999059974A1 Tetraisoquinololine derivatives as modulators of dopamine d3 receptors
11/25/1999WO1999059973A1 Carboxamide compounds, compositions, and methods for inhibiting parp activity
11/25/1999WO1999059972A1 Carboxy substituted carboxamide derivatives as tachykinin receptor antagonists
11/25/1999WO1999059971A1 Novel 4-phenylpiperidines for the treatment of pruritic dermatoses
11/25/1999WO1999059969A1 Compositions comprising 2-phenyl-indole compounds and estrogen formulations
11/25/1999WO1999059966A1 METHOD OF LOCKING 1α-OH OF VITAMIN D COMPOUNDS IN AXIAL ORIENTATION
11/25/1999WO1999059964A1 Novel analogs of 16-hydroxyeicosatetraenoic acid
11/25/1999WO1999059961A1 Selective anti-mycobacterial preparations, method for producing the same and pharmaceutical compositions
11/25/1999WO1999059960A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999WO1999059959A1 Benzamide derivatives for the treatment of diseases mediated by cytokines
11/25/1999WO1999059957A1 Compounds having reversible inhibiting activity of carnitine palmitoyl-transferase
11/25/1999WO1999059640A2 Metal complexes derivatized with folate for use in diagnostic and therapeutic applications
11/25/1999WO1999059639A1 Solid preparations for oral administration of drugs relating to genes
11/25/1999WO1999059635A1 Use of a cox-2 inhibitor and a nk-1 receptor antagonist for treating inflammation
11/25/1999WO1999059634A1 Anti-inflammatory eye drops
11/25/1999WO1999059629A1 Humanized antibodies that recognize verotoxin ii and cell line producing same
11/25/1999WO1999059628A2 Combination therapy for the treatment of tumors
11/25/1999WO1999059621A1 Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis c infection
1 ... 6404 6405 6406 6407 6408 6409 6410 6411 6412 6413 6414 6415 6416 6417 6418 6419 6420 6421 6422 6423 6424 ... 7860